IL6 and COVID-19: There are 306 ongoing registered trials for the treatment of COVID-19 as of 4 April 2020, including trials of IL-6- and IL-6-receptor (IL-6R)-blocking antibodies, as severe COVID-19 causes strong expression of chemokines and inflammatory cytokines, especially IL-6 and IL1RA (37).